

Accomplishing an unprecedented 115 kg GMP campaign of MK-0616 through innovation and strategic planning

Gao Shang

Merck & Co Inc, New York

gao.shang@merck.com

This presentation takes the audience on a journey of the discovery, development and manufacturing of MK-0616, the “largest small molecule” from Merck. The talk introduces the unprecedented synthetic challenges and showcases MSD’s scientific excellence in chemistry, novel technologies and industrial leading business model to enable the successful clinical manufacturing of this cyclic peptide drug candidate. Topics such as novel synthetic approaches, biocatalysis and protein engineering are discussed in detail.